Tag: Eli Lilly and Company

Akouos AK-OTOF yields positive results in hearing restoration Phase 1/2 study

businessnewstoday- January 25, 2024

In a significant advancement for medical science and hearing loss treatment, Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), has ... Read More

Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma

businessnewstoday- December 31, 2023

Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable ... Read More

Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024

businessnewstoday- November 29, 2023

In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE: LLY) has revealed plans to inaugurate its ... Read More

Lilly bags Zepbound FDA approval for obesity treatment

businessnewstoday- November 9, 2023

The U.S. Food and Drug Administration has granted approval to Eli Lilly's Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP ... Read More

Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain

businessnewstoday- October 3, 2023

Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in ... Read More

Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks

businessnewstoday- October 2, 2023

The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant development announced jointly by Boehringer Ingelheim and ... Read More

Eli Lilly receives FDA response letter for eczema treatment lebrikizumab

businessnewstoday- October 2, 2023

Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for lebrikizumab, a treatment aimed at addressing moderate-to-severe ... Read More

Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

businessnewstoday- August 24, 2023

Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More

Lilly expands portfolio with $1.9bn acquisition of Versanis Bio

businessnewstoday- August 15, 2023

In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More

Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research

businessnewstoday- August 15, 2023

Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More